Tumor Treating Fields vs Standard Therapy in Treatment-Resistant Metastatic NSCLC
1. The median OS was 13.2 months with TTFields arm vs 9.9 months with standard arm, with an HR of...
Patritumab Deruxtecan in EGFR-mutated NSCLC post EGFR TKI and Chemotherapy
1. The objective response rate was 29.8% (1% complete response, 66% partial response) with a PFS of 5.5 months and...
Nivolumab/Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma
1. Pooled overall survival and progression-free survival HR were found to be 0.95 and 0.88 for nivolumab/ipilimumab vs. nivolumab. 2....
![Addition of bevacizumab fails to benefit overall survival in newly diagnosed glioblastoma [RTOG 0825 trial]](https://www.2minutemedicine.com/wp-content/uploads/2014/02/AFIP-00405558-Glioblastoma-Radiology-e1381685577283-350x250.jpg)
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
1. Median progression-free survival was shown to be 27.7 months in the vorasidenib group vs 11.1 months in the placebo...
Perioperative Nivolumab and Chemotherapy in Stage III NSCLC
1. The pathological complete response rate for the experimental group was improved compared to the control group. 2. Progression-free survival...
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases
1. The immune subtype demonstrated an improved progression-free survival (HR 0.37) and overall survival (HR 0.56) compared with the canonical...
Checkpoint Inhibitors With Radiotherapy in Patients With Advanced Solid Tumors
1. Stereotactic body radiotherapy in addition to immune checkpoint inhibitors has similar progression-free survival to immune checkpoint inhibitors alone, with...
Lazertinib Versus Gefitinib as First-line Treatment in EGFR-mutated Advanced NSCLC
1. Progression-free survival was longer in the lazertinib group vs the gefitinib group (20.6 months vs 9.7 months, with HR...
Induction Therapy for Patients with Metastatic Colorectal Cancer and Liver Metastases
1. In patients with right-sided or RAS/BRAFV600E mutated tumors, the PFS was favorable with FOLFOXIRI plus bevacizumab compared to FOLFOX...
Neoadjuvant FOLFOX compared to Chemoradiotherapy in Locally Advanced Rectal Cancer
1. Patients who were randomized to neoadjuvant FOLFOX vs standard chemoradiation had similar disease-free and overall survival rates. 2. There...
